Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

How Is Bristol-Myers Squibb's Stock Performance Compared to Other General Drug Manufacturers?

Bristol-Myers Squibb Company (BMY), headquartered in Princeton, New Jersey, is a leading biopharmaceutical company focused on developing treatments for serious diseases such as cancer, inflammatory, immunologic, cardiovascular, and fibrotic diseases. Valued at $83.1 billion by market cap, its strong oncology portfolio includes blockbuster drug Opdivo and other drugs like Revlimid, Pomalyst, Sprycel, Yervoy, and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis.

Companies worth $10 billion or more are generally described as “large-cap stocks,” BMY fits right into that category, signifying its substantial size, stability, and dominance in its industry. Bristol-Myers Squibb's prominent position in the pharma industry results from its well-established brand reputation, extensive research and development capabilities, varied product portfolio, and worldwide presence. The company's dedication to innovation and delivering high-quality products has enabled it to develop numerous groundbreaking drugs.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.